Quadria Capital
Quadria Capital is an Asia-focused healthcare private-equity firm investing in regional healthcare leaders through growth, significant-minority and majority positions. Its India activity spans healthcare delivery, life sciences, medical devices and associated services.
At a glance
- Founded
- 2012
- Footprint
- Singapore / Delhi
- Stage
- Growth (healthcare-only)
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Quadria Capital uses a growth (healthcare-only) approach across Hospitals, pharma, diagnostics, medtech.
Current evidence
Quadria closed its oversubscribed Fund III at US$1.07 billion in May 2025 and said the fund was already nearly 40% deployed, including Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 review also documents the Akums IPO partial exit and continued growth at Encube and Maxivision.
Strategy
Growth (healthcare-only)
Sector focus
Hospitals, pharma, diagnostics, medtech
Current signal
Quadria closed its oversubscribed Fund III at US$1.07 billion in May 2025 and said the fund was already nearly 40% deployed, including Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 review also documents the Akums IPO partial exit and continued growth at Encube and Maxivision.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.